|
Select publications
Bajetta E et al. Safety and efficacy of two different doses of capecitabine in the treatment
of advanced breast cancer in older women. J Clin Oncol 2005;23(10):2155-61. Abstract
Blum JL et al. A Phase II trial of combination therapy with capecitabine and weekly
paclitaxel for metastatic breast cancer (MBC): Preliminary results in taxane-naïve
patients. Poster. San Antonio Breast Cancer Symposium 2004;Abstract 5053.
Blum JL et al. ABI-007 nanoparticle paclitaxel: Demonstration of anti-tumor activity in
taxane-refractory metastatic breast cancer. Proc ASCO 2003;Abstract 64.
Blum JL et al. Long term disease control in taxane-refractory metastatic breast cancer
treated with nab paclitaxel. ASCO 2004;Abstract 543.
Chen EX, Siu LL. Development of molecular targeted anticancer agents: Successes,
failures and future directions. Curr Pharm Des 2005;11(2):265-72. Abstract
Cobleigh MA et al. A phase I/II dose-escalation trial of bevacizumab in previously
treated metastatic breast cancer. Semin Oncol 2003;30(5 Suppl 16):117-24. Abstract
Gradishar WJ et al. Capecitabine plus paclitaxel as front-line combination therapy for
metastatic breast cancer: A multicenter phase II study. J Clin Oncol 2004;22(12):2321-7.
Abstract
Gradishar WJ et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared
with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-803. Abstract
Gralow JR. Optimizing the treatment of metastatic breast cancer. Breast Cancer Res Treat 2005;89(Suppl 1):9-15. Abstract
Hampton T. Monoclonal antibody therapies shine in breast cancer clinical trials. JAMA 2005;293(24):2985-9. No abstract available
Hennessy BT et al. Lower dose capecitabine has a more favorable therapeutic index in
metastatic breast cancer: Retrospective analysis of patients treated at MD Anderson
Cancer Center and a review of capecitabine toxicity in the literature. Ann Oncol 2005;16(8):1289-96. Abstract
Hudis CA. Clinical implications of antiangiogenic therapies. Oncology (Williston Park) 2005;19(4 Suppl 3):26-31. Abstract
Ignoffo RJ. Overview of bevacizumab: A new cancer therapeutic strategy targeting
vascular endothelial growth factor. Am J Health Syst Pharm 2004;61(21 Suppl 5):21-6. Abstract
Kaklamani V, O’Regan RM. New targeted therapies in breast cancer. Semin Oncol 2004;31(2
Suppl 4):20-5. Abstract
Leonard R et al. Optimizing the management of HER2-negative metastatic breast
cancer with capecitabine (Xeloda). Semin Oncol 2004;31(5 Suppl 10):21-8. Abstract
Miller KD et al. E2100: A randomized phase III trial of paclitaxel versus paclitaxel plus
bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. Presentation. ASCO 2005a. No abstract available
Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab
plus capecitabine in patients with previously treated metastatic breast cancer. J Clin
Oncol 2005b;23(4):792-9. Abstract
Miller KD. Recent translational research: Antiangiogenic therapy for breast cancer —
Where do we stand? Breast Cancer Res 2004;6(3):128-32. Abstract
Moses MA et al. A role for antiangiogenic therapy in breast cancer. Curr Oncol Rep 2004;6(1):42-8. Abstract
O’Shaughnessy J et al. ABI-007 (ABRAXANE ), a nanoparticle albumin-bound
(nab) paclitaxel demonstrates superior efficacy vs Taxol in MBC: A phase III trial. Presentation. San Antonio Breast Cancer Symposium 2003;Abstract 44.
O’Shaughnessy J et al. Superior survival with capecitabine plus docetaxel combinationtherapy
in anthracycline-pretreated patients with advanced breast cancer: Phase III
trial results. J Clin Oncol 2002; 20(12): 2812-23. Abstract
O’Shaughnessy JA et al. Weekly nanoparticle albumin paclitaxel (Abraxane) results in
longterm disease control in patients with taxane-refractory metastatic breast cancer. San Antonio Breast Cancer Symposium 2004;Abstract 1070.
Rugo HS. Bevacizumab in the treatment of breast cancer: Rationale and current data. Oncologist 2004;9(Suppl 1):43-9. Abstract
Schneider BP, Miller KD. Angiogenesis of breast cancer. J Clin Oncol 2005;23(8):1782-90.
No abstract available
Seidman A et al. CALGB 9840: Phase III study of weekly paclitaxel via a 1-hour infusion
versus standard 3-hour infusion every third week on the treatment of metastasic breast
cancer with trastuzumab for HER2 positive metastatic breast cancer and randomized
for trastuzumab in HER2 normal metastatic breast cancer. Presentation. ASCO
2004;Abstract 512.
Tabernero J et al. A multicentre, randomised phase II study of weekly or 3-weekly
docetaxel in patients with metastatic breast cancer. Ann Oncol 2004;15(9):1358-65.
Abstract
Zamora P et al. Capecitabine (X) as single agent in elderly patients (p) with metastatic
breast cancer (MBC). Proc ASCO 2005;Abstract 843.
|
